JP2021513972A - 社会的機能障害の治療方法 - Google Patents

社会的機能障害の治療方法 Download PDF

Info

Publication number
JP2021513972A
JP2021513972A JP2020543492A JP2020543492A JP2021513972A JP 2021513972 A JP2021513972 A JP 2021513972A JP 2020543492 A JP2020543492 A JP 2020543492A JP 2020543492 A JP2020543492 A JP 2020543492A JP 2021513972 A JP2021513972 A JP 2021513972A
Authority
JP
Japan
Prior art keywords
disorder
hcl
disorders
formula
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513972A5 (https=
JPWO2019161236A5 (https=
Inventor
デイビッド・ブラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of JP2021513972A publication Critical patent/JP2021513972A/ja
Publication of JP2021513972A5 publication Critical patent/JP2021513972A5/ja
Publication of JPWO2019161236A5 publication Critical patent/JPWO2019161236A5/ja
Priority to JP2023198772A priority Critical patent/JP2024023383A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020543492A 2018-02-16 2019-02-15 社会的機能障害の治療方法 Pending JP2021513972A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023198772A JP2024023383A (ja) 2018-02-16 2023-11-24 社会的機能障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862761253P 2018-02-16 2018-02-16
US62/761,253 2018-02-16
PCT/US2019/018263 WO2019161236A1 (en) 2018-02-16 2019-02-15 Methods of treating social function disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023198772A Division JP2024023383A (ja) 2018-02-16 2023-11-24 社会的機能障害の治療方法

Publications (3)

Publication Number Publication Date
JP2021513972A true JP2021513972A (ja) 2021-06-03
JP2021513972A5 JP2021513972A5 (https=) 2022-02-15
JPWO2019161236A5 JPWO2019161236A5 (https=) 2022-02-15

Family

ID=65529920

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543492A Pending JP2021513972A (ja) 2018-02-16 2019-02-15 社会的機能障害の治療方法
JP2023198772A Pending JP2024023383A (ja) 2018-02-16 2023-11-24 社会的機能障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023198772A Pending JP2024023383A (ja) 2018-02-16 2023-11-24 社会的機能障害の治療方法

Country Status (3)

Country Link
US (3) US20210008030A1 (https=)
JP (2) JP2021513972A (https=)
WO (1) WO2019161236A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883246B (zh) 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
CN118576586A (zh) * 2018-12-06 2024-09-03 住友制药美国公司 治疗神经和精神疾病的方法
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
WO2023049721A1 (en) 2021-09-23 2023-03-30 Sunovion Pharmaceuticals Inc. Methods of treating metabolic disorders
TW202600129A (zh) * 2024-02-23 2026-01-01 美商住友製藥美國公司 烏洛托隆（ulotaront）鹽酸鹽的製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512926A (ja) * 2009-12-04 2013-04-18 スノビオン プハルマセウトイカルス インコーポレイテッド 多環式化合物及びその使用方法
JP7146782B2 (ja) * 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512926A (ja) * 2009-12-04 2013-04-18 スノビオン プハルマセウトイカルス インコーポレイテッド 多環式化合物及びその使用方法
JP7146782B2 (ja) * 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROPSYCHOPHARMACOLOGY, vol. Vol.41, Suppl.1, JPN6022050538, 2016, pages 393 - 394, ISSN: 0004932058 *

Also Published As

Publication number Publication date
US20250302800A1 (en) 2025-10-02
US20240050401A1 (en) 2024-02-15
WO2019161236A1 (en) 2019-08-22
US20210008030A1 (en) 2021-01-14
JP2024023383A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
JP2021513972A (ja) 社会的機能障害の治療方法
JP7453148B2 (ja) 塩、結晶形態、およびその製造方法
JP7268026B2 (ja) 非ラセミ混合物およびその使用
JP6203841B2 (ja) カルバメート／尿素誘導体
EP3636640B1 (en) Crystal of heterocyclidene acetamide derivative
CN107531642B (zh) 咪唑衍生物
JP6831376B2 (ja) トリアゾール誘導体
WO2008080290A1 (en) Selective m4 receptor antagonist and its medical use
WO2018038255A1 (ja) 環状アミン誘導体の結晶及びその医薬用途
JP2019509987A (ja) Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体
JP2018531253A6 (ja) トリアゾール誘導体
WO2023136279A1 (ja) 置換ピペリジン化合物の結晶並びに置換ピペリジン化合物の塩及びそれらの結晶
JP4435090B2 (ja) スルホンアミド含有インドール化合物の結晶およびその製造方法
HK40083601B (zh) 取代的哌啶化合物及其用途
JP2013507420A (ja) パルドプルノックスの多形
WO2012084873A1 (en) 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230725